Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Servier_(oncology_business,_2021)
|
| gptkbp:CEO |
gptkb:Brian_Goff
|
| gptkbp:develops_treatment_for |
gptkb:acute_myeloid_leukemia
rare genetic diseases pyruvate kinase deficiency |
| gptkbp:focusesOn |
oncology
rare diseases cellular metabolism |
| gptkbp:founded |
2008
|
| gptkbp:founder |
gptkb:David_Schenkein
gptkb:Tak_Mak gptkb:Lewis_Cantley |
| gptkbp:headquarters_location |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Agios Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableProduct |
gptkb:PYRUKYND
gptkb:TIBSOVO |
| gptkbp:numberOfEmployees |
approximately 300 (2023)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
precision medicine
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:AGIO
|
| gptkbp:website |
https://www.agios.com/
|
| gptkbp:bfsParent |
gptkb:Polaris_Partners
|
| gptkbp:bfsLayer |
4
|